Adicet Bio Inc 's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics

What is ROE for Adicet Bio Inc in the first quarter 2026?
Adicet Bio Inc recorded a cumulative net loss of $-109 million during 12 months ending in the first quarter 2026, resulting in a negative return on equity (ROE) of -80.35%.

Within the Major Pharmaceutical Preparations industry 231 other companies had a higher return on equity. While return on equity, the total ranking has deteriorated compared to the fourth quarter 2025 from 3089 to 3460.

What is ROE?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Equity ROE▼

None ▼

Return on Equity ROE▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Equity	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter	(Mar 31 2025) I. Quarter
Y / Y Equity Change	-13.24 %	-14.68 %	-48.4 %	-43.27 %	-
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in Millions	-109	-117	-115	-119	-117
Return On Equity (TTM)	-80.35 %	-82.96 %	-77.9 %	-68.48 %	-59.05 %
ACET's Total Ranking	# 3460	# 3089	# 2961	# 2950	# 3001
Equity (TTM) in Millions	140	159	109	133	161
Seq. Equity Change	-12.02 %	45.87 %	-18.17 %	-17.39 %	-13.48 %
Seq. Net Income Change	-	-	-	-	-

Back to ACET Management Effectiveness >> ACET's 5 Years Annual ROE >> Compare ACET ROE to its Competitors

Return On Equity Company Ranking
Within:	No.
Industry	# 232
Sector	# 513
Overall	# 3460

Return On Equity Statistics
High	Average	Low
117.95 %	-22.6 %	-369.98 %
(Mar 31 2021)		(Dec 31 2018)

News about Adicet Bio Inc Return on Equity ROE

ADI-001 A Promising Off-the-Shelf CAR T Cell Therapy Augmenting Treatment for Autoimmune Diseases

Adicet Bio, Inc. a clinical-stage biotechnology firm, is making strides in the field of allogeneic, gamma delta T cell therapies aimed at treating autoimmune diseases and cancer. In recent developments, the company presented significant clinical biomarker data at the American College of Rheumatology (ACR) Convergence 2024, which highlights the potential impact of their novel treatment, ADI-001. Overview of ADI-001ADI-001 is an innovative off-the-shelf chimeric antigen receptor (CAR) T cell therapy developed by Adicet Bio. Designed to target autoimmune conditions and cancers, the treatment utilizes gamma delta T cells to create a potentially more effective and accessible option than traditional autologous CAR T cell therapies. The therapy aims to exploit the natural ability of these cells to recognize stressed cells, potentially improving outcomes for patients with autoimmune diseases.

ACET Annual Return On Equity	(Dec 31 2025) 2025	(Dec 31 2024) 2024	(Dec 31 2023) 2023	(Dec 31 2022) 2022	(Dec 31 2021) 2021
Total Equity in Millions	159	187	170	292	303
Y / Y Equity Change	-14.68 %	9.66 %	-41.79 %	-3.56 %	176.01 %
Net Income in Millions	-117	-117	-143	-70	-62
Y / Y Net Income Change	-	-	-	-	-
Return On Equity	-73.36 %	-62.76 %	-83.83 %	-23.87 %	-20.45 %

Back to ACET Management Effectiveness >> ACET's 5 Years Annual ROE >> Compare ACET ROE to its Competitors

More Return On Equity Ratios
Major Pharmaceutical Preparations Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
ACET's' Return on Equity at Yahoo Finance
ACET's Roe Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for ACET's Competitors
Subscribers only: Roe for Adicet Bio Inc 's Suppliers
Subscribers only: Return On Equity for ACET's Customers

Companies with similar Return On Equity at Mar 31 2026, within Healthcare Sector

ROE

Date modified: 2026-09-08T15:11:42+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.